Develops pharmaceutical products, consumer health products, and medical devices. Acquires rights to pharmaceutical assets through strategic transactions. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.2× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 17% a year on average.
Sales run at $324.3M a year. A small number, but proof the product has real buyers.
There is $68.7M in the vault; even if every debt were paid off, $12.5M would remain.
A loss of $3.9M against $324.3M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.